Literature DB >> 18585900

Chronic psychotropic drug treatment causes differential expression of connexin 43 and GFAP in frontal cortex of rats.

S Hossein Fatemi1, Timothy D Folsom, Teri J Reutiman, Twinkle Pandian, Natalie N Braun, Kari Haug.   

Abstract

Astrocytic markers glial fibrillary acidic protein (GFAP) and connexin 43 (CX43) are known to have altered expression in brains of subjects with psychiatric disorders including autism and major depression. The current study investigated whether GFAP and CX43 expressions are affected by several commonly used psychotropic medications (clozapine, fluoxetine, haloperidol, lithium, olanzapine, and valproic acid). Using SDS-PAGE and western blotting technique, we observed that CX43 protein expression in prefrontal cortex was significantly increased following chronic treatment with fluoxetine and clozapine, while it was significantly decreased by haloperidol and lithium. GFAP protein expression was significantly decreased following chronic treatment with clozapine and valproic acid. These results suggest that astroglial markers GFAP and CX43 could be potential targets for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18585900     DOI: 10.1016/j.schres.2008.05.016

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  16 in total

Review 1.  Gap junction channels as potential targets for the treatment of major depressive disorder.

Authors:  Qian Ren; Zhen-Zhen Wang; Shi-Feng Chu; Cong-Yuan Xia; Nai-Hong Chen
Journal:  Psychopharmacology (Berl)       Date:  2017-11-25       Impact factor: 4.530

2.  Gap junction dysfunction in the prefrontal cortex induces depressive-like behaviors in rats.

Authors:  Jian-Dong Sun; Yan Liu; Yu-He Yuan; Jing Li; Nai-Hong Chen
Journal:  Neuropsychopharmacology       Date:  2011-12-21       Impact factor: 7.853

Review 3.  The Role of Brain Microvascular Endothelial Cell and Blood-Brain Barrier Dysfunction in Schizophrenia.

Authors:  Sovannarath Pong; Rakesh Karmacharya; Marianna Sofman; Jeffrey R Bishop; Paulo Lizano
Journal:  Complex Psychiatry       Date:  2020-09-14

4.  Brexpiprazole Reduces 5-HT7 Receptor Function on Astroglial Transmission Systems.

Authors:  Kouji Fukuyama; Eishi Motomura; Motohiro Okada
Journal:  Int J Mol Sci       Date:  2022-06-12       Impact factor: 6.208

5.  Reduced connexin 43 immunolabeling in the orbitofrontal cortex in alcohol dependence and depression.

Authors:  José Javier Miguel-Hidalgo; Barbara A Wilson; Syed Hussain; Ashish Meshram; Grazyna Rajkowska; Craig A Stockmeier
Journal:  J Psychiatr Res       Date:  2014-04-16       Impact factor: 4.791

6.  Decreased GFAP expression and improved functional recovery in contused spinal cord of rats following valproic acid therapy.

Authors:  Marzieh Darvishi; Taki Tiraihi; Seyed A Mesbah-Namin; AliReza Delshad; Taher Taheri
Journal:  Neurochem Res       Date:  2014-09-10       Impact factor: 3.996

Review 7.  From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders.

Authors:  Gerard Sanacora; Mounira Banasr
Journal:  Biol Psychiatry       Date:  2013-06-15       Impact factor: 13.382

Review 8.  Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue.

Authors:  Grazyna Rajkowska; Craig A Stockmeier
Journal:  Curr Drug Targets       Date:  2013-10       Impact factor: 3.465

9.  Evaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strains.

Authors:  Cristina S Benton; Brooke H Miller; Sean Skwerer; Oscar Suzuki; Laura E Schultz; Michael D Cameron; J S Marron; Mathew T Pletcher; Tim Wiltshire
Journal:  Psychopharmacology (Berl)       Date:  2011-11-24       Impact factor: 4.530

10.  Effects of Atypical Antipsychotics, Clozapine, Quetiapine and Brexpiprazole on Astroglial Transmission Associated with Connexin43.

Authors:  Kouji Fukuyama; Motohiro Okada
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.